Vulva cancer

This early-stage trial tests an experimental medicine called BI 3822971 in adults with advanced or metastatic solid cancers, such as lung, head and neck, breast, esophageal, bladder, vulvar, or cervical cancer, who have no standard treatment options left. The goal is to find out …

This study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…

This study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …

This trial tests an experimental drug called STAR0602, which is designed to help the immune system attack cancer cells. It is being studied in people with advanced solid tumors that have not responded to standard treatments. The drug is given alone or combined with chemotherapy, …

This study tests whether adding tivozanib (a drug that targets blood vessel growth) to atezolizumab (an immunotherapy) can help the immune system attack cancers that normally resist immunotherapy. The trial includes people with several cancer types like bile duct, pancreatic, pro…

This study tests a combination of two drugs, becotatug vedotin and zimberelimab, in 30 people with recurrent or metastatic cervical, vulvar, or vaginal cancer. The goal is to see if the treatment can shrink tumors and control the disease. Participants must have already tried at l…

This study tests an experimental drug called YH32364 in adults with advanced solid tumors that have high levels of EGFR and have not responded to previous treatments. The trial has two parts: first, finding a safe dose in about 30 people, then testing that dose in 50 people with …

This study tests whether a single infusion of a patient's own genetically engineered immune cells (E7 TCR-T cells) can shrink or eliminate HPV-related cancers before the patient receives standard treatment like chemo-radiation or surgery. The trial enrolls 15 adults with advanced…

This study tests a new immunotherapy for people with advanced HPV-related cancers, such as cervical, throat, anal, and penile cancers. Participants receive specially engineered immune cells designed to attack cancer cells carrying the HPV16 virus. The goal is to see if this treat…

This early-stage study tests whether adding the HIV drug nelfinavir to standard chemotherapy (cisplatin) and radiation can safely treat advanced vulvar cancer that has spread and cannot be surgically removed. About 25 adults with stage II-IVA vulvar cancer will take part. The mai…

This study tests whether two drugs, pembrolizumab and lenvatinib, can shrink tumors in people with vulvar cancer that has come back, spread, or is too advanced for surgery or radiation. About 42 participants will receive the combination. The main goal is to see how many have thei…

This phase II trial is testing whether the immunotherapy drug dostarlimab, alone or combined with bevacizumab, can control recurrent gynecological clear cell carcinoma better than standard chemotherapy. About 198 women with this rare cancer type will be randomly assigned to one o…

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…

This Phase 2 trial is testing whether two drugs, pembrolizumab and lenvatinib, can shrink or control vulvar cancer that cannot be surgically removed. About 80 participants will receive the combination in 21-day cycles. The study will measure tumor response and track side effects.

This study tests a treatment called electrochemotherapy for women whose vulvar cancer has come back. It combines a chemotherapy drug (bleomycin) with electric pulses to help the drug enter cancer cells more effectively. The goal is to shrink tumors and avoid major surgery. Only 1…

This study tests a new drug called CNSI-Fe(II), which is injected directly into tumors. It uses iron to trigger a type of cell death called ferroptosis, aiming to control advanced solid tumors like lung, pancreas, and colorectal cancers. The trial involves 54 adults whose current…

This study aims to see if matching the extent of surgery to the specific type of vulvar cancer (based on HPV infection and p53 gene changes) can reduce the chance of the cancer coming back. About 249 women with early-stage vulvar squamous cell carcinoma will take part. The goal i…

This early-phase study tests a new radioactive drug, [177Lu]Lu-AKIR001, in 15 adults with advanced solid tumors (like thyroid, head and neck, cervical, vulvar, or lung cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and sid…

This study tests whether using MRI scans to guide brachytherapy (a type of internal radiation) can better target tumors in gynecologic cancers like cervical, uterine, vaginal, vulvar, and bladder cancers. The goal is to see if MRI guidance reduces radiation exposure to nearby hea…

This study tests a drug called belzutifan in people with a rare, hard-to-treat type of gynecologic cancer called clear cell carcinoma. The goal is to see if the drug can shrink tumors or stop them from growing. About 32 participants will receive the drug, and researchers will mon…

This study tests whether taking multiple MRI scans before, during, and after standard radiation therapy can help doctors see how tumors change. Researchers will enroll people with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer, or pediatric glioma. The g…

This study compares a dye called ICG alone against the standard two-method approach (ICG plus a radioactive tracer) to find cancer in lymph nodes of women with early vulvar cancer. About 58 women will take part. If ICG alone works just as well, it could simplify surgery and reduc…

This study looks at whether the things people buy at stores—like pain relievers or digestive aids—could be early warning signs of cancer. Researchers will compare the shopping habits of 2900 people, some diagnosed with cancer and some not, to see if certain purchases happen more …

This phase 2 trial tests whether cryocompression therapy, alone or combined with the drug cilostazol, can prevent peripheral neuropathy in people receiving paclitaxel for gynecologic cancers. Peripheral neuropathy causes numbness, pain, or tingling in the hands and feet and is a …

This study looks at whether adding pelvic floor physical therapy before standard radiation treatment can help reduce pain and sexual problems in women with cervical, vaginal, vulvar, uterine, or anal cancer. About 20 participants will receive education on using a vaginal dilator …

This trial tests a blended e-health program designed to help women with breast or gynecologic cancer cope with fear of their cancer returning or worsening. The program combines remote group sessions with online modules that teach skills to manage unhelpful thoughts and promote he…

This study tests a behavioral program to help women who have had pelvic radiation use vaginal dilators more regularly. Dilators can prevent or treat vaginal narrowing that makes exams or sex painful. 88 women will be randomly assigned to either the program (with coping strategies…

This study tests a personalized physical activity program for women over 60 with gynecologic cancers who are receiving chemotherapy or other systemic treatments. The program includes a wearable activity tracker and a smartphone app, plus optional features like an exercise partner…

This study tests whether Reiki therapy can reduce anxiety and pain in people receiving brachytherapy for gynecologic cancers. 70 participants will either receive Reiki or standard care during their treatment. Researchers will measure changes in anxiety, pain, and mood using quest…

This study tests whether using a virtual reality headset during brachytherapy (a type of internal radiation for cervical cancer) can reduce pain, anxiety, and the need for medication. Twenty women will try VR during one treatment session and compare it to a session without VR. Th…

This phase 2 trial tests whether a vaginal DHEA suppository can safely improve vaginal health in 25 women who had radiation for gynecologic, anal, or rectal cancer. Radiation often causes dryness, burning, and pain, similar to menopause. DHEA is a hormone replacement that may hel…

This study tests whether a daily probiotic pill (Pendulum Glucose Control) can safely reduce stomach and bowel problems in people receiving radiation for cancers of the pelvis, such as prostate, gynecologic, or lower GI cancers. About 20 adults will take the probiotic during thei…

This study tests whether a mobile cognitive training app can reduce 'chemobrain'—memory and thinking problems caused by chemotherapy—in people with gynecologic cancers. Sixty-four participants will use the app on their own phones while undergoing chemotherapy and complete thinkin…

This study will test tumor samples from 350 adults with gynecological cancers (endometrial, ovarian, cervical, vulvar, and vaginal) to see how often they have high levels of the HER2 protein. Researchers will use two standard lab tests to measure HER2. The goal is to learn how co…

This observational registry is gathering data from 500 adults whose gynecologic cancer has returned after prior radiation therapy. Doctors are using reirradiation or other ablative strategies as part of standard care, and the registry will track how well these treatments control …

This study is observing 300 women with female sexual organs who are receiving radiotherapy for certain cancers. Researchers want to understand why some patients have more sexual side effects than others. They will track sexual quality of life and look at radiation doses to find p…

This pilot study is testing whether a 7-day integrative oncology retreat called 'Via Shalva' is practical and helpful for women who have finished primary treatment for breast or gynecologic cancer. Thirty participants will either attend the retreat or receive usual follow-up care…

This study is testing whether regular patient surveys and a special blood test (circulating tumor DNA) can spot vulva cancer returning earlier than standard check-ups. About 295 women with vulva cancer will fill out symptom surveys every four months and give blood samples for two…

This study follows 200 women with gynecologic cancer and their partners to see how sexual function changes over time. Researchers use questionnaires at diagnosis, 6 months, and 12 months after treatment. The goal is to understand when sexual counseling might be most helpful, with…

This study looks at whether regular groin ultrasound scans can safely replace surgery to check for cancer spread in women with early-stage vulvar cancer. About 30 women will be randomly assigned to either have groin surgery or get ultrasound checks every 2 months for a year. The …

This study looks at whether changes in a blood marker called CRP can help predict how well immunotherapy works in women with advanced gynecologic cancers (cervical, endometrial, ovarian, or vulvar). Researchers will track CRP levels in 120 women receiving immunotherapy plus chemo…

This study tests whether 3D-printed custom applicators can deliver radiation more precisely than standard cylinder applicators for gynecologic cancers like endometrial, vaginal, and vulvar cancer. Ten participants will receive brachytherapy with a personalized 3D-printed mold. Th…

This study looks at how the dose and storage conditions of a dye called indocyanine green (ICG) affect its ability to find sentinel lymph nodes during surgery for cervical, endometrial, and vulvar cancers. Researchers will enroll 30 patients to see which approach works best and s…

This study collects tumor and blood samples from over 1,000 people with certain cancers (ovarian, breast, head and neck, cervical, vulva, and sarcoma). Researchers will analyze the samples to find links between genetic changes, the immune system, and how the cancer behaves. Parti…

This study will follow 200 patients with vulvovaginal cancer who received radiation therapy (with or without chemotherapy) to see how the disease returns and how their quality of life changes over time. Researchers will also look at certain biological markers. The goal is to gath…

This study compares two common risk assessment tools—the Charlson Comorbidity Index (CCI) and the POSSUM score—to see which better predicts complications in women undergoing surgery for gynecologic cancers. Researchers will track complications, hospital stay length, and 30-day de…

This study aims to learn how gene and protein changes in gynecologic tumors affect cancer behavior and treatment response. Researchers will collect tumor tissue and blood samples from 1,000 people with ovarian, uterine, cervical, or other gynecologic cancers. The goal is to bette…